• Publications
  • Influence
Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion
When added to standard therapy, GLP-1 infusion improved regional and global LV function in patients with AMI and severe systolic dysfunction after successful primary angioplasty.
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.
In DCM, GLP-1-(9-36) mimics the effects ofGLP- 1-36 in stimulating myocardial glucose uptake and improving left ventricular (LV) and systemic hemodynamics through insulinomimetic as opposed to insulinotropic effects.
Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy
rGLP-1 dramatically improved LV and systemic hemodynamics in conscious dogs with advanced DCM induced by rapid pacing and may be a useful metabolic adjuvant in decompensated heart failure.
Peptide YY is secreted after oral glucose administration in a gender-specific manner.
Findings show that PYY and GLP-1 are colocalized and cosecreted from L cells and that total secretion of PYY is higher in females than in males, but fasting PYY levels and PYY secretion in response to oral glucose were not in any way correlated with BMI.
Exercise increases muscle GLUT-4 levels and insulin action in subjects with impaired glucose tolerance.
It is demonstrated that chronic exercise training without changes in body composition improves peripheral insulin action in subjects with impaired glucose tolerance, and improved oral glucose tolerance was observed.
GLP‐1 (9–36) Amide, Cleavage Product of GLP‐1 (7–36) Amide, Is a Glucoregulatory Peptide
Glucagon‐like peptide‐1 (GLP‐1) (7–36) amide is a glucoregulatory hormone with insulinotropic and insulinomimetic actions that is determined to be mediated through its principal metabolite, GLP-1 (9–36] amide (GLp‐1m).
Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men.
It is concluded that insulin resistance is associated with a decrease in Leydig cell T secretion in men with a spectrum of insulin sensitivity.